Amarin Corp Plc (AMRN)

[couldbebetter]

Rose, Generic Lovaza has been a problem for AMRN forever. Management has
not found any viable solution to this problem. Maybe if AMRN were owned
by BP they would have figured out a solution to this. Vascepa usage will
not be optimized in the hands of John Thero, it may be optimized once it
is in the hands of the "right" BP. That always was and will continue to
be the best way for Vascepa sales to be optimized.

My guess is that the right BP would be more aggressive legally and would
find a way for the FDA to step in to protect the US population from
ineffective medications such as Lovaza. At least this will not be a
problem for Vascepa in Europe.